Spring Bank Pharmaceuticals Inc (NASDAQ:SBPH) – Analysts at William Blair lifted their Q1 2019 earnings estimates for shares of Spring Bank Pharmaceuticals in a note issued to investors on Monday, March 11th. William Blair analyst Y. Xu now anticipates that the company will post earnings per share of ($0.43) for the quarter, up from their previous forecast of ($0.51). William Blair also issued estimates for Spring Bank Pharmaceuticals’ Q2 2019 earnings at ($0.43) EPS, Q3 2019 earnings at ($0.43) EPS, Q4 2019 earnings at ($0.44) EPS, FY2019 earnings at ($1.72) EPS, Q1 2020 earnings at ($0.53) EPS, Q2 2020 earnings at ($0.60) EPS, Q3 2020 earnings at ($0.66) EPS, Q4 2020 earnings at ($0.73) EPS and FY2020 earnings at ($2.52) EPS.
Spring Bank Pharmaceuticals (NASDAQ:SBPH) last announced its quarterly earnings results on Monday, March 11th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.17.
Shares of Spring Bank Pharmaceuticals stock opened at $10.44 on Thursday. Spring Bank Pharmaceuticals has a 1 year low of $8.14 and a 1 year high of $15.73. The firm has a market cap of $172.09 million, a price-to-earnings ratio of -5.58 and a beta of 0.80.
Institutional investors and hedge funds have recently bought and sold shares of the company. Rhumbline Advisers acquired a new stake in shares of Spring Bank Pharmaceuticals during the third quarter worth $122,000. Blair William & Co. IL acquired a new stake in shares of Spring Bank Pharmaceuticals during the third quarter worth $123,000. JPMorgan Chase & Co. lifted its holdings in shares of Spring Bank Pharmaceuticals by 464.0% during the third quarter. JPMorgan Chase & Co. now owns 12,712 shares of the company’s stock worth $153,000 after buying an additional 10,458 shares in the last quarter. Pegasus Asset Management Inc. acquired a new stake in shares of Spring Bank Pharmaceuticals during the fourth quarter worth $195,000. Finally, Dimensional Fund Advisors LP acquired a new stake in shares of Spring Bank Pharmaceuticals during the fourth quarter worth $206,000. 43.18% of the stock is owned by institutional investors.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapeutics using small molecule nucleic acid hybrid (SMNH) chemistry platform. The company's lead SMNH product candidate is inarigivir soproxil, for the treatment of chronic hepatitis B virus (HBV).
Featured Story: Net Asset Value
Receive News & Ratings for Spring Bank Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.